Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $2,046,629.04 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew Posard sold 18,996 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the sale, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Trading Up 1.1%

Shares of NASDAQ HALO traded up $1.24 during midday trading on Thursday, hitting $109.68. The stock had a trading volume of 1,983,627 shares, compared to its average volume of 1,833,846. The company has a market capitalization of $12.45 billion, a price-to-earnings ratio of 32.74, a PEG ratio of 0.40 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $111.15. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a fifty day moving average price of $95.33 and a 200 day moving average price of $77.80.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company earned $1.54 EPS. The company’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the topic of a number of recent research reports. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. TD Cowen boosted their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Talon Private Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $839,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth approximately $359,000. Tidal Investments LLC grew its position in shares of Halozyme Therapeutics by 13.5% during the second quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock worth $14,895,000 after buying an additional 22,707 shares in the last quarter. WINTON GROUP Ltd increased its stake in shares of Halozyme Therapeutics by 704.6% in the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock worth $4,723,000 after buying an additional 52,848 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in Halozyme Therapeutics by 6.7% in the second quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company’s stock valued at $3,614,000 after acquiring an additional 2,889 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.